Compare EMO & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EMO | MNKD |
|---|---|---|
| Founded | 2011 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2004 |
| Metric | EMO | MNKD |
|---|---|---|
| Price | $50.56 | $3.93 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $8.08 |
| AVG Volume (30 Days) | 31.6K | ★ 3.4M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | ★ 6.70% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $348,966,000.00 |
| Revenue This Year | N/A | $26.63 |
| Revenue Next Year | N/A | $14.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $41.54 | $2.23 |
| 52 Week High | $56.33 | $6.51 |
| Indicator | EMO | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 51.28 | 63.51 |
| Support Level | $49.73 | $3.24 |
| Resistance Level | $53.33 | $4.28 |
| Average True Range (ATR) | 1.09 | 0.15 |
| MACD | 0.29 | 0.08 |
| Stochastic Oscillator | 49.81 | 96.08 |
ClearBridge Energy Midstream Opportunity Fund Inc is a non-diversified, closed-end management investment company. Its investment objective is to provide long-term investors with a high level of total return with an emphasis on cash distributions. The Fund considers investments in midstream entities as those entities that provide midstream services including the gathering, transporting, processing, fractionation, storing, refining, and distribution of oil, natural gas liquids and natural gas.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.